We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current BBIO market cap is 8.94B. The company's latest EPS is USD -2.8216 and P/E is -16.73.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 211.12M | 2.17M | 2.73M | 5.88M | 116.63M |
| Operating Income | 343k | -56.9M | -191.75M | -226.03M | -104.37M |
| Net Income | -35.22M | -73.46M | -162.04M | -265.05M | -167.42M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 8.25M | 69.72M | 77.65M | 9.3M | 221.9M |
| Operating Income | -474.48M | -546.72M | -512.2M | -607.37M | -592.7M |
| Net Income | -448.72M | -562.54M | -481.18M | -643.2M | -535.76M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 849.33M | 794.38M | 664.98M | 919.34M | 881.64M |
| Total Liabilities | 1.89B | 1.88B | 1.88B | 2.38B | 2.52B |
| Total Equity | -1.04B | -1.08B | -1.22B | -1.46B | -1.64B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 703.59M | 1.01B | 623.04M | 546.38M | 919.34M |
| Total Liabilities | 595.7M | 1.88B | 1.87B | 1.89B | 2.38B |
| Total Equity | 106.26M | -867M | -1.24B | -1.34B | -1.46B |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -219.54M | -144.83M | -325.4M | -520.73M | -199.24M |
| Investing | 22.75M | 25.79M | 64.02M | 60.78M | -1.6M |
| Financing | 279.55M | 273.82M | 274.53M | 748.46M | 60.33M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -399.71M | -497.93M | -419.49M | -527.72M | -520.73M |
| Investing | -52.99M | -200.83M | 453.15M | 54.03M | 60.78M |
| Financing | 447.19M | 736.45M | -13.13M | 451.54M | 748.46M |
| Market Cap | 8.94B |
| Price to Earnings Ratio | -16.73 |
| Price to Sales Ratio | 40.4 |
| Price to Cash Ratio | 13.16 |
| Price to Book Ratio | -6.15 |
| Dividend Yield | - |
| Shares Outstanding | 189.88M |
| Average Volume (1 week) | 3.09M |
| Average Volume (1 Month) | 3.49M |
| 52 Week Change | 66.78% |
| 52 Week High | 48.6809 |
| 52 Week Low | 21.72 |
| Spread (Intraday) | 1.49 (3.09%) |
| Company Name | BridgeBio Pharma Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.bridgebio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
